BTZ043 is primarily investigated for its potential as an antitubercular agent, showing significant activity against Mycobacterium tuberculosis, including drug-resistant strains. It functions by inhibiting the DprE1 enzyme, which is crucial for bacterial cell wall synthesis. This makes it a promising candidate for the development of new tuberculosis treatments, particularly in addressing multidrug-resistant and extensively drug-resistant tuberculosis cases. Research is ongoing to evaluate its efficacy, safety, and potential for clinical use.